Our Product

We're developing a revolutionary intranasal device for patients with anaphylaxis

Published Studies

Results from dose ranging pharmacokinetic and pharmacodynamic effects of nasal spray epinephrine versus autoinjector epinephrine in healthy participants

AAAI 2021 Dose Ranging Study Poster Screenshot

Bryn Pharma presented their findings from a 5 Period, 5-way crossover study during a virtual meeting at the American Academy of Allergy, Asthma & Immunology.

Results suggested that the bi-dose nasal spray may produce a more favorable epinephrine exposure profile and alleviation of anaphylactic symptoms as compared with the autoinjector.

Click here to access the full poster

Results from Bryn Pharma preclinical canine study presented at ACAAI National Conference

Nasal Congestion Study Poster Screenshot

At the 2019 American College of Allergy, Asthma & Immunology National Conference (ACAAI) in Houston, Bryn Pharma presented findings from their preclinical study assessing intranasal epinephrine effects on pharmacokinetics and heart rate in a nasal congestion canine model. The full manuscript of the study was released in Respiratory Research on April 3, 2020.

In the study, intranasal epinephrine entered the blood plasma even in the presence of nasal congestion.

Click here to access the full poster

Click to view the full study at Respiratory Research

Results from a canine study on pharmacokinetics and heart rate effects

Bryn Pharma recently released more clinical data in Pharmacology Research & Perspectives. The study examined pharmacokinetic and heart rate effects of Bryn Pharma's intranasal (IN) epinephrine versus intramuscular (IM) injection. This comparative study was performed in a canine model.

Results from the study were released on April 17, 2020. Overall, IN epinephrine demonstrated advantages over IM epinephrine, including rapid increase in plasma epinephrine and lack of increased heart rate over time.

Click to view the full study at Pharmacology Research & Perspectives

Bryn Pharma publishes promising results from study assessing pharmacokinetic and pharmacodynamic effects of intranasal epinephrine versus intramuscular epinephrine

Comparative Delivery Study Poster Screenshot

The Bryn Pharma team recently released an open-label, 2-part comparative bioavailability study to compare pharmacokinetic and pharmacodynamics after epinephrine intranasal (IN) or intramuscular (IM).

Results included comparative measures. Two epinephrine doses in the same nostril led to increased epinephrine absorption versus 2 IN doses in opposite nostrils and 2 IM doses;2 epinephrine doses in the same or opposite nostrils led to substantially greater epinephrine absorption vs 1 epinephrine IM dose. Epinephrine IN was also found to be safe and well-tolerated.

Click here to access the full poster

Bryn Pharma healthcare professional study reveals significant preference for bi-dose intranasal epinephrine spray

HCP Preference Study Poster Screenshot

In November 2019, Bryn Pharma released the results of a multicenter, randomized crossover healthcare professional preference study between the EpiPen® auto-injector and the bi-dose intranasal epinephrine spray. These results were presented at the American College of Allergy, Asthma & Immunology National Conference (ACAAI), taking place November 7–11, in Houston, TX.

Results from the study show significant preference in 56 healthcare professionals for the bi-dose epinephrine nasal spray over the EpiPen® auto-injector based on an array of assessments.

Click here to access the full poster

Bryn Pharma releases promising patient perspective results from preference study

Patient Preference Study Poster Screenshot

In October 2019, Bryn Pharma released the results of a multicenter, randomized crossover patient preference study between the EpiPen® auto-injector and the bi-dose epinephrine nasal spray were presented at the American Academy of Pediatrics (AAP) National Conference in New Orleans, LA.

Results from the study show patients’ significant preference for the bi-dose epinephrine nasal spray over the EpiPen® auto-injector on various metrics including comfort, ease of use, portability, and overall preference. The study assessed other preference factors as well.

Click here to access the full poster

Our Device

We are developing BRYN-NDS1C, an epinephrine nasal spray, for the treatment of anaphylaxis. Studies have shown that, in spite of practice and prescription guidelines, the majority of people at risk for anaphylaxis don't always carry one of their auto-injectors, and even fewer carry two epinephrine auto-injectors. This is due in part to size and cost of the products, putting patients at greater risk of severe complications during an allergic reaction. BRYN-NDS1C is designed to provide patients with a life-saving treatment that is needle free, fits in a pocket, is easy to use, and complies with practice parameters.

Over the last three years, we and our research and clinical collaborators have completed extensive preclinical and clinical trials of BRYN-NDS1C designed to support regulatory submission and approval to market the product candidate. In early 2019, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to BRYN-NDS1C. We have successfully completed pilot studies demonstrating the proof of concept of the innovative treatment, and in October 2019 we completed dosing in the pivotal human trial designed to support U.S. approval to market the product candidate. BRYN-NDS1C is not currently approved for sale by the FDA or any international regulatory authority.

Check back for updates on our device.

Product image